Document Detail


Syk is a novel target of arsenic trioxide (ATO) and is involved in the toxic effect of ATO in human neutrophils.
MedLine Citation:
PMID:  19925860     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The anticancer dug arsenic trioxide (ATO) is known to be toxic for human mononuclear and neutrophil cell populations by a mechanism that needs to be further investigated. Due to the well-characterized role of Syk kinase in phagocytosis and because activation and involvement of Syk in response to ATO treatment has never been reported in any cells, we decided to determine whether or not Syk is involved in the mode of action of ATO. Human neutrophils were freshly isolated and incubated in vitro with ATO and the role of Syk was evaluated in different neutrophil functions. We found that ATO increased phosphorylation of Syk and this was reversed by piceatannol, a Syk-specific pharmacological inhibitor. In addition, ATO increased the phagocytic ability of neutrophils and degranulation via Syk activation. Finally, using both pharmacological inhibition and cellular depletion of Syk via an antisense approach, we found that this kinase is involved in apoptosis. We conclude that Syk activation is an important step in the mode of action of ATO in mature immune cells such as neutrophils and is involved in rapid, intermediate and lengthy biological processes. This is the first study to report that Syk is activated by ATO.
Authors:
Francis Antoine; Jamila Ennaciri; Denis Girard
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-11-16
Journal Detail:
Title:  Toxicology in vitro : an international journal published in association with BIBRA     Volume:  24     ISSN:  1879-3177     ISO Abbreviation:  Toxicol In Vitro     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-09     Completed Date:  2010-06-22     Revised Date:  2011-11-02    
Medline Journal Info:
Nlm Unique ID:  8712158     Medline TA:  Toxicol In Vitro     Country:  England    
Other Details:
Languages:  eng     Pagination:  936-41     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
Affiliation:
Laboratoire de Recherche en Inflammation et Physiologie des Granulocytes, Université du Québec, INRS-Institut Armand-Frappier, Laval, QC, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / toxicity*
Antisense Elements (Genetics) / pharmacology
Apoptosis / drug effects
Arsenicals
Cell Adhesion / drug effects
Cell Degranulation / drug effects
Cell Separation
Enzyme Activation / drug effects
Enzyme Inhibitors / pharmacology
Humans
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors,  drug effects*
Membrane Proteins / metabolism
Neutrophils / drug effects*,  enzymology
Oxides / toxicity*
Phagocytosis / drug effects
Phosphorylation
Protein-Tyrosine Kinases / antagonists & inhibitors,  drug effects*
Spleen / drug effects*,  enzymology*
Stilbenes / pharmacology
Grant Support
ID/Acronym/Agency:
MOP-89534//Canadian Institutes of Health Research
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Antisense Elements (Genetics); 0/Arsenicals; 0/Enzyme Inhibitors; 0/Intracellular Signaling Peptides and Proteins; 0/Membrane Proteins; 0/Oxides; 0/Stilbenes; 1327-53-3/arsenic trioxide; 4339-71-3/3,3',4,5'-tetrahydroxystilbene; EC 2.7.10.1/Protein-Tyrosine Kinases; EC 2.7.10.1/Syk kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  MiR-320 and miR-494 affect cell cycles of primary murine bronchial epithelial cells exposed to benzo...
Next Document:  Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effectiv...